@Haplo from the MTH Annual Report to Shareholders 30 Sep 2020:
Limestone Well Project (Limestone)
- Mithril 100%; and
- Auteco Minerals can earn up to an 80% interest in the project by completing exploration expenditure of A$2.5 million over five years
Highlights include:
- Maiden RC drill programme by Mithril’s JV partner – Auteco Minerals (AUT.ASX) intersects multiple broad zones of shallow high-grade vanadium-titanium, including;
- 20m @ 0.48% V2O5 & 6.5% TiO2 from 12 metres and 72m @ 0.46% V2O5 & 8.6% TiO2 from 52 metres in LWRC003;
- 12m @ 0.72% V2O5 & 8.5% TiO2 from 12 metres and 24m @ 0.50% V2O5 & 6.2% TiO2 from 48 metres, and 56m @ 0.46% V2O5 & 6.1% TiO2 from 164 metres in LWRC005; and
- 20m @ 0.50% V2O5 & 6.5% TiO2 from 64 metres and 116m @ 0.36% V2O5 & 11.0% TiO2 from 104 meters in LWRC006.
- Follow the successful drilling, Auteco has elected to continue sole-funding the exploration work at Limestone Well by completing exploration expenditure of $1.5M by August 2021 to earn an initial 60% interest
- Forums
- ASX - By Stock
- First Mining Announces Drill Results from its Pickle Crow Gold Project
@Haplo from the MTH Annual Report to Shareholders 30 Sep...
Featured News
NEWS
Is oil undervalued?
Add FFM (ASX) to my watchlist
|
|||||
Last
73.5¢ |
Change
0.010(1.38%) |
Mkt cap ! $353.3M |
Open | High | Low | Value | Volume |
74.0¢ | 75.0¢ | 72.0¢ | $1.075M | 1.463M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 12602 | 73.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
74.0¢ | 11629 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 12602 | 0.730 |
2 | 20900 | 0.725 |
2 | 70581 | 0.720 |
3 | 71014 | 0.715 |
2 | 62000 | 0.710 |
Price($) | Vol. | No. |
---|---|---|
0.740 | 11629 | 2 |
0.745 | 27895 | 5 |
0.750 | 26031 | 5 |
0.775 | 10000 | 1 |
0.780 | 1455 | 1 |
Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
Featured News
NEWS
Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo
NEWS
Is oil undervalued?
NEU
Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
FFM (ASX) Chart |